Do analysts prefer TENX or BYSI?

Tenax Therapeutics presently has a consensus target price of $29.67, suggesting a potential upside of 176.48%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Tenax Therapeutics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TENX or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tenax Therapeutics N/A -56.32% -53.12% BeyondSpring N/A N/A -14.00%

Do analysts recommend SRZN or BYSI?

Surrozen presently has a consensus price target of $42.00, suggesting a potential upside of 79.72%. Given Surrozen's stronger consensus rating and higher possible upside, analysts clearly believe Surrozen is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Surrozen 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SRZN or BYSI more profitable?

BeyondSpring has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. BeyondSpring's return on equity of 0.00% beat Surrozen's return on equity. Company Net Margins Return on Equity Return on Assets Surrozen -4,810.50% -4,055.04% -154.08% BeyondSpring N/A N/A -14.00%

Do analysts rate TKNO or BYSI?

Alpha Teknova presently has a consensus price target of $8.00, indicating a potential upside of 81.82%. Given Alpha Teknova's stronger consensus rating and higher possible upside, analysts plainly believe Alpha Teknova is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alpha Teknova 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend NAGE or BYSI?

Niagen Bioscience currently has a consensus price target of $10.50, indicating a potential upside of 206.12%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Niagen Bioscience is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer BYSI or EDIT?

Editas Medicine has a consensus price target of $5.40, suggesting a potential upside of 121.31%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Editas Medicine is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Editas Medicine 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

BeyondSpring (BYSI) Competitors

$1.65 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.66 +0.02 (+0.91%)

As of 04:10 PM Eastern

Compare

BYSI vs. TENX, SRZN, TKNO, NAGE, and EDIT

Should you buy BeyondSpring stock or one of its competitors? MarketBeat compares BeyondSpring with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BeyondSpring include Tenax Therapeutics (TENX), Surrozen (SRZN), Alpha Teknova (TKNO), Niagen Bioscience (NAGE), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry.

How does BeyondSpring compare to Tenax Therapeutics?

Tenax Therapeutics (NASDAQ:TENX) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

BeyondSpring's return on equity of 0.00% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-56.32%	-53.12%
BeyondSpring	N/A	N/A	-14.00%

Tenax Therapeutics has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

In the previous week, Tenax Therapeutics and Tenax Therapeutics both had 1 articles in the media. BeyondSpring's average media sentiment score of 1.29 beat Tenax Therapeutics' score of 0.93 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
Tenax Therapeutics	Positive
BeyondSpring	Positive

BeyondSpring has higher revenue and earnings than Tenax Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A
BeyondSpring	$1.75M	38.77	-$1.01M	-$0.14	N/A

Tenax Therapeutics presently has a consensus target price of $29.67, suggesting a potential upside of 176.48%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Tenax Therapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 3.1% of Tenax Therapeutics shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

BeyondSpring beats Tenax Therapeutics on 8 of the 14 factors compared between the two stocks.

How does BeyondSpring compare to Surrozen?

Surrozen (NASDAQ:SRZN) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

BeyondSpring has lower revenue, but higher earnings than Surrozen. BeyondSpring is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	77.97	-$242.03M	-$37.59	N/A
BeyondSpring	$1.75M	38.77	-$1.01M	-$0.14	N/A

Surrozen has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

66.6% of Surrozen shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 31.7% of Surrozen shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BeyondSpring has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. BeyondSpring's return on equity of 0.00% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
BeyondSpring	N/A	N/A	-14.00%

Surrozen presently has a consensus price target of $42.00, suggesting a potential upside of 79.72%. Given Surrozen's stronger consensus rating and higher possible upside, analysts clearly believe Surrozen is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Surrozen had 4 more articles in the media than BeyondSpring. MarketBeat recorded 5 mentions for Surrozen and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.29 beat Surrozen's score of 0.74 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
Surrozen	Positive
BeyondSpring	Positive

Summary

Surrozen beats BeyondSpring on 11 of the 17 factors compared between the two stocks.

How does BeyondSpring compare to Alpha Teknova?

Alpha Teknova (NASDAQ:TKNO) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

BeyondSpring has lower revenue, but higher earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than BeyondSpring, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	5.82	-$17.26M	-$0.32	N/A
BeyondSpring	$1.75M	38.77	-$1.01M	-$0.14	N/A

13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 12.5% of Alpha Teknova shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alpha Teknova has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

BeyondSpring has a net margin of 0.00% compared to Alpha Teknova's net margin of -41.07%. BeyondSpring's return on equity of 0.00% beat Alpha Teknova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-41.07%	-24.32%	-16.34%
BeyondSpring	N/A	N/A	-14.00%

Alpha Teknova presently has a consensus price target of $8.00, indicating a potential upside of 81.82%. Given Alpha Teknova's stronger consensus rating and higher possible upside, analysts plainly believe Alpha Teknova is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Alpha Teknova and Alpha Teknova both had 1 articles in the media. BeyondSpring's average media sentiment score of 1.29 beat Alpha Teknova's score of 0.94 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
Alpha Teknova	Positive
BeyondSpring	Positive

Summary

BeyondSpring beats Alpha Teknova on 10 of the 15 factors compared between the two stocks.

How does BeyondSpring compare to Niagen Bioscience?

Niagen Bioscience (NASDAQ:NAGE) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Niagen Bioscience currently has a consensus price target of $10.50, indicating a potential upside of 206.12%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Niagen Bioscience is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Niagen Bioscience has higher revenue and earnings than BeyondSpring. BeyondSpring is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	2.11	$17.38M	$0.21	16.33
BeyondSpring	$1.75M	38.77	-$1.01M	-$0.14	N/A

Niagen Bioscience has a net margin of 14.29% compared to BeyondSpring's net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat BeyondSpring's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
BeyondSpring	N/A	N/A	-14.00%

In the previous week, Niagen Bioscience had 2 more articles in the media than BeyondSpring. MarketBeat recorded 3 mentions for Niagen Bioscience and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.29 beat Niagen Bioscience's score of 0.62 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
Niagen Bioscience	Positive
BeyondSpring	Positive

Niagen Bioscience has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

Summary

Niagen Bioscience beats BeyondSpring on 12 of the 16 factors compared between the two stocks.

How does BeyondSpring compare to Editas Medicine?

BeyondSpring (NASDAQ:BYSI) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

BeyondSpring has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market.

BeyondSpring has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. BeyondSpring's return on equity of 0.00% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Editas Medicine	-281.59%	-677.39%	-58.25%

In the previous week, Editas Medicine had 5 more articles in the media than BeyondSpring. MarketBeat recorded 6 mentions for Editas Medicine and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.29 beat Editas Medicine's score of -0.16 indicating that BeyondSpring is being referred to more favorably in the media.

Company	Overall Sentiment
BeyondSpring	Positive
Editas Medicine	Neutral

BeyondSpring has higher earnings, but lower revenue than Editas Medicine. BeyondSpring is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	38.77	-$1.01M	-$0.14	N/A
Editas Medicine	$40.52M	5.90	-$160.06M	-$1.23	N/A

Editas Medicine has a consensus price target of $5.40, suggesting a potential upside of 121.31%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Editas Medicine is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

BeyondSpring and Editas Medicine tied by winning 8 of the 16 factors compared between the two stocks.

Get BeyondSpring News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BYSI vs. The Competition

Export

Metric	BeyondSpring	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$67.85M	$3.29B	$6.47B	$11.73B
Dividend Yield	N/A	2.33%	2.67%	5.56%
P/E Ratio	-11.79	10.85	20.64	22.08
Price / Sales	38.77	301.53	503.66	108.52
Price / Cash	14.52	120.36	43.20	54.62
Price / Book	-2.80	8.21	10.50	6.82
Net Income	-$1.01M	$23.89M	$3.56B	$337.41M
7 Day Performance	-3.51%	-3.00%	-2.02%	-0.96%
1 Month Performance	8.55%	-1.64%	0.66%	1.68%
1 Year Performance	-43.30%	40.20%	21.85%	26.88%

BeyondSpring Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BYSI BeyondSpring	0.1793 of 5 stars	$1.65 flat	N/A	-34.3%	$67.85M	$1.75M	N/A	80	Positive News
TENX Tenax Therapeutics	3.1534 of 5 stars	$10.77 -1.6%	$29.67 +175.5%	+82.5%	$285.67M	N/A	N/A	9
SRZN Surrozen	3.7051 of 5 stars	$24.57 +6.1%	$42.00 +70.9%	+143.5%	$285.26M	$7.49M	N/A	80	News Coverage Gap Up
TKNO Alpha Teknova	2.3937 of 5 stars	$5.13 -1.0%	$8.00 +55.9%	-24.4%	$275.02M	$40.52M	N/A	240	Positive News
NAGE Niagen Bioscience	4.1243 of 5 stars	$3.44 -2.8%	$14.67 +326.4%	-74.3%	$273.96M	$129.42M	16.38	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BYSI) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeyondSpring (BYSI) Competitors

BYSI vs. TENX, SRZN, TKNO, NAGE, and EDIT

How does BeyondSpring compare to Tenax Therapeutics?

Summary

How does BeyondSpring compare to Surrozen?

Summary

How does BeyondSpring compare to Alpha Teknova?

Summary

How does BeyondSpring compare to Niagen Bioscience?

Summary

How does BeyondSpring compare to Editas Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI vs. The Competition

BeyondSpring Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BeyondSpring (BYSI) Competitors

BYSI vs. TENX, SRZN, TKNO, NAGE, and EDIT

How does BeyondSpring compare to Tenax Therapeutics?

Is TENX or BYSI more profitable?

Which has more risk and volatility, TENX or BYSI?

Does the media refer more to TENX or BYSI?

Which has stronger earnings and valuation, TENX or BYSI?

Do analysts prefer TENX or BYSI?

Do institutionals and insiders have more ownership in TENX or BYSI?

Summary

How does BeyondSpring compare to Surrozen?

Which has higher earnings and valuation, SRZN or BYSI?

Which has more volatility & risk, SRZN or BYSI?

Do institutionals & insiders hold more shares of SRZN or BYSI?

Is SRZN or BYSI more profitable?

Do analysts recommend SRZN or BYSI?

Does the media prefer SRZN or BYSI?

Summary

How does BeyondSpring compare to Alpha Teknova?

Which has preferable valuation and earnings, TKNO or BYSI?

Do institutionals and insiders believe in TKNO or BYSI?

Which has more volatility & risk, TKNO or BYSI?

Is TKNO or BYSI more profitable?

Do analysts rate TKNO or BYSI?

Does the media refer more to TKNO or BYSI?

Summary

How does BeyondSpring compare to Niagen Bioscience?

Do insiders and institutionals have more ownership in NAGE or BYSI?

Do analysts recommend NAGE or BYSI?

Which has preferable valuation and earnings, NAGE or BYSI?

Is NAGE or BYSI more profitable?

Does the media refer more to NAGE or BYSI?

Which has more risk & volatility, NAGE or BYSI?

Summary

How does BeyondSpring compare to Editas Medicine?

Which has more volatility & risk, BYSI or EDIT?

Is BYSI or EDIT more profitable?

Does the media favor BYSI or EDIT?

Which has better valuation & earnings, BYSI or EDIT?

Do analysts prefer BYSI or EDIT?

Do insiders & institutionals hold more shares of BYSI or EDIT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI vs. The Competition

BeyondSpring Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools